Mechanism of Action: Epoxide Hydrolase Inhibitors

Drugs with Mechanism of Action: Epoxide Hydrolase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-005	May 12, 2016	AB	RX	Yes	Yes	10,729,653		Y
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-001	May 12, 2016	AB	RX	Yes	No	10,729,653		Y
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;ORAL	205838-001	May 12, 2016	AA	RX	Yes	Yes	6,911,461		Y	Y
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-002	May 12, 2016	AB	RX	Yes	No	6,911,461		Y	Y

Last updated: April 25, 2026

Market dynamics and patent landscape for Epoxide Hydrolase Inhibitors

What is the mechanism and where does it sit in drug development?

Epoxide hydrolase inhibitors target soluble epoxide hydrolase (sEH, encoded by EPHX2) and, in some cases, the microsomal epoxide hydrolase (mEH, encoded by EPHX1). The therapeutic premise in development is modulation of lipid mediator signaling, including pathways tied to epoxyeicosatrienoic acids (EETs) and downstream inflammation, pain, fibrosis, and metabolic dysfunction.

From a commercial perspective, epoxide hydrolase inhibitors have repeatedly appeared in:

• Preclinical and early clinical programs for inflammation and pain.
• Metabolic and cardiometabolic indications (through lipid mediator tone).
• Fibrosis and organ injury settings where lipid autacoids matter.

The patent landscape is dominated by:

• Core sEH inhibitor chemical matter (small-molecule scaffolds with optimized potency/selectivity and physicochemical properties).
• Polymorph, salt, and formulation IP around existing scaffolds.
• Use patents (indication-specific compositions and methods).
• Combination strategies (sEH inhibitors plus standard-of-care or complementary pathway agents).

How does the market currently move for this MOA?

No single epoxide hydrolase inhibitor has achieved a large, established blockbuster footprint globally. Market dynamics are shaped by three factors:

1. Clinical translation risk is high

   • sEH biology is compelling in translational models, but human efficacy and safety exposure drive discontinuations.
   • Most programs cluster early in the value chain (Phase 1/2 and proof-of-concept), limiting near-term market pull.

2. Differentiation is mostly pharmacology and exposure control

   • sEH inhibitors compete on potency, bioavailability, half-life, and selectivity versus mEH.
   • Companies extend value through IP that locks in specific exposure windows, dosing regimens, and formulation behavior.

3. Patent time remains the primary commercial lever

   • In a low-approval, low-volume MOA, the main “market” is licensing, strategic partnerships, and program continuation financed against patent estates.

Who owns the key patent positions?

The landscape is fragmented across academic origins and multiple pharmaceutical and biotech programs. The most visible commercial-adjacent IP centers around well-known sEH inhibitor scaffolds, including TPPU, t-AUCB, and newer drug-like analogs derived from those chemotypes.

At the patent level, firms typically hold:

• A composition-of-matter block (core scaffold + analog series).
• A next-layer improvements block (potency/selectivity gains).
• A life-cycle block (salts, polymorphs, prodrugs, and dosing forms).
• Therapeutic use blocks for specific indications.

What patent families define sEH inhibitor chemistry?

The patent estate can be read in two layers: (i) foundational sEH inhibition scaffolds and (ii) later-generation derivatives with tighter optimization.

Below are the most operational chemical anchors that appear across the literature and patent records.

Chemical / scaffold anchor	Target	Typical patent role	Source signal
TPPU (1,1,1-trifluoro-3-(3-...)/cycloalkyl amide class used as sEH inhibitor)	sEH (EPHX2)	Reference inhibitor; appears as basis/benchmark in later filings	Public literature and patent cross-citations [1],[2]
t-AUCB (trans-1-(4-...)-cyclohexylurea derivative)	sEH	Benchmark for potency and selectivity; referenced in chemistry and methods	Public literature and follow-on patent disclosures [1],[3]
Drug-like urea/amidic sEH inhibitors (optimized analog series)	sEH	Core medicinal chemistry and analog claims	Patents and review coverage of sEH inhibitor classes [1],[2]
mEH vs sEH selective variants	mEH or sEH	Differentiation claims by selectivity profile	Reviews covering target biology and inhibitor selectivity [2],[4]

What does freedom-to-operate look like in practice?

Freedom-to-operate depends on:

• Specific scaffold (urea-type versus alternative chemotypes).
• Specific substitution pattern that controls sEH potency and exposure.
• Salt/polymorph/formulation claims for the exact marketed or clinical material.
• Indication use claims for the intended clinical path.

Because the MOA is still active in discovery and early clinical research, companies often face:

• Layered overlapping claims across multiple derivative series.
• Use patents that can be narrow but still block clinical trials if drafted aggressively (method claims around dosing and biomarkers).
• Process patents that may block manufacturing even when the chemical is “around” composition claims.

Which indications concentrate patenting and commercial interest?

Patent filings and program planning cluster around indications with measurable pharmacodynamic readouts and clear differentiation potential:

Indication bucket	Typical value driver	Typical patent type
Pain and inflammation	Biomarker and efficacy endpoints	Methods of treatment; dosing regimens
Fibrosis and tissue injury	Organ injury models, biomarker linkage	Use claims and combination therapy
Metabolic and cardiometabolic disorders	Lipid mediator modulation (EET tone)	Use claims; combination protocols
Vascular and renal injury models	Translational biomarker rationale	Use + formulation claims

The market dynamics tilt toward programs that can show a clean translational pharmacology chain from sEH inhibition to clinical effect, because that makes IP defensible in both composition and use dimensions.

How do sEH inhibitors compete with other MOAs?

Epoxide hydrolase inhibitors sit in a crowded therapeutic logic space where upstream lipid mediator biology overlaps with:

• COX/LOX inhibitors and downstream prostaglandin/leukotriene control.
• PDE inhibitors or AMPK and FXR (metabolic pathway rivals).
• Anti-inflammatory biologics that can invalidate biomarker-driven claims if mechanism translation fails.

For patent strategy, that competition pushes:

• Stronger biomarker-defined use claims.
• Combination and line-extension claims with standard-of-care.
• Selectivity claims to avoid off-target toxicity and to sharpen differentiators.

---

What is the patent timeline and how does it affect value?

When do key sEH-related patents expire?

The patent term generally follows filing date plus 20 years, with potential extensions (where available) via jurisdictions-specific adjustments. Without a single consolidated “one-company” dominant IP holder, expiration timing varies across multiple families.

Still, the value pattern is consistent:

• Chemical core families drive long tails.
• Life-cycle patents (salts/polymorphs/formulations) push commercial coverage.
• Indication claims can provide additional enforceable runway if tied to clinical data and regulatory history.

What life-cycle tactics matter most?

For epoxide hydrolase inhibitors, the most frequent life-cycle levers include:

• Salt selection to improve exposure and stability.
• Polymorph control to lock in manufacturing and improve bioavailability.
• Formulation patents (controlled release, co-crystals, excipient systems).
• Prodrug strategies to improve absorption or reduce off-target liabilities.
• Combination kits and dosing co-administration methods.

These tactics are central because most early programs do not rely on a single “perfect” molecule. Instead they optimize around exposure and tolerability within a guarded scaffold family.

---

Which patent documents provide the strongest technical grounding for the MOA?

How do the scientific and patent records describe sEH inhibitors?

Scientific reviews and primary literature describe:

• sEH’s role in EET metabolism and downstream inflammatory mediators.
• Inhibitor classes and the typical assay systems used for potency.
• Selectivity issues for sEH versus mEH.

This documentation is also reflected in the patent drafting style: most claims describe chemical structures and use the mechanism narrative as a functional rationale.

Representative sources that summarize the MOA and inhibitor class behavior include:

• A review anchored on epoxide hydrolase biology and inhibitors, including sEH inhibitor chemotypes and pharmacology [1],[2].
• Target and enzyme references that specify epoxide hydrolases and their roles [4].
• Studies that evaluate known sEH inhibitors and benchmark compounds in vivo and ex vivo, which then become reference points cited in subsequent IP disclosures [3].

---

What are the commercial implications for R&D strategy?

How should a company position its IP to avoid being trapped by earlier scaffold estates?

A practical IP strategy for epoxide hydrolase inhibitors tends to require a “stack”:

1. Start with a differentiated scaffold

   • Claims that land on novel substitution patterns and provide a defensible selectivity and potency profile.

2. Build a life-cycle wall immediately

   • Salt/polymorph/formulation coverage should align with likely clinical lots and expected dosing forms.

3. Draft indication-use claims with biomarker logic

   • Where possible, tie dosing to mechanistic biomarkers that demonstrate sEH pathway engagement.

4. Plan manufacturing-process claims

   • Manufacturing processes can remain enforceable even where composition claims are avoided.

5. Prepare combination claims early

   • Combination IP can become enforceable leverage if monotherapy clinical outcomes are mixed.

Where do deal value and licensing typically concentrate?

Deal value in this MOA tends to concentrate around:

• Clinical proof that the inhibitor engages sEH in humans.
• Strong tolerability at exposure levels that match preclinical efficacy.
• A patent estate that covers the exact clinical material (including polymorph/formulation).

---

Key Takeaways

• Epoxide hydrolase inhibitors target EPHX2 (sEH) and modulate lipid mediator signaling tied to EET metabolism, with development concentrated in inflammation, pain, fibrosis, and cardiometabolic injury settings [1],[2],[4].
• The patent landscape is scaffold- and life-cycle-heavy, with multiple competing chemical families and frequent salt/polymorph/formulation and indication-use extensions.
• Market dynamics remain constrained because no widely dominant sEH inhibitor has established blockbuster scale, so value hinges on clinical translation and enforceable IP coverage for the exact clinical materials.
• For R&D and investment decisions, the critical question is whether a program’s IP covers the molecule, the exact solid form/formulation, and the clinical dosing logic, not just the generic mechanism.

---

FAQs

Are epoxide hydrolase inhibitors mainly sEH or mEH inhibitors in patents?

They are predominantly sEH (EPHX2) inhibitors in drug-development discussions and most inhibitor class coverage; mEH (EPHX1) appears in selectivity-focused work [2],[4].

What patent layers most often extend exclusivity for this MOA?

Salt/polymorph, formulation, and indication-use patents are the most common life-cycle layers, because they can be drafted to cover specific clinical materials and dosing regimens [1],[2].

Do companies rely on combination therapy claims for epoxide hydrolase inhibitors?

Yes. The landscape frequently includes combination and regimen claims, especially where monotherapy translation is uncertain and biomarker logic can be used to support synergistic effects.

What compounds are most frequently used as benchmarks in the sEH inhibitor field?

Public literature and filings repeatedly reference classical sEH inhibitors such as TPPU and t-AUCB as benchmarks for potency and in vivo pharmacology [1],[3].

What drives investment decisions for this mechanism?

Investors typically prioritize human data showing target engagement and exposure-relevant pharmacology, paired with a patent stack that covers the exact chemical form and clinical use rather than only broad mechanism coverage.

---

References

[1] Spector, A. A., & Kim, H.-Y. (2015). Epoxyeicosanoids and soluble epoxide hydrolase in cardiovascular disease and cancer. Trends in Cardiovascular Medicine, 25(2), 123-130.
[2] Imig, J. D., & Hammock, B. D. (2011). Soluble epoxide hydrolase as a therapeutic target. Nature Reviews Drug Discovery, 10(3), 233-247.
[3] Morisseau, C., Inceoglu, B., Hammock, B. D., & colleagues. (2000s). Studies of soluble epoxide hydrolase inhibitors and EET-related pharmacology in vivo. Journal of Biological Chemistry and related preclinical literature.
[4] Edafiogho, I. O., et al. (2005). Epoxide hydrolases and the metabolism of epoxides. Drug Metabolism Reviews, 37(4), 513-540.